Quantcast

Latest Hepatic encephalopathy Stories

2010-04-16 06:00:00

VIENNA, April 16 /PRNewswire/ -- Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL)...

2010-03-24 16:57:00

SILVER SPRING, Md., March 24 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease. This is a new use for Xifaxan (rifaximin), a drug that has been approved for the treatment of traveler's diarrhea. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Hepatic encephalopathy is a worsening of brain function that can...

2010-02-23 14:12:00

SAN DIEGO, Feb. 23 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010. AST-120 adsorbs ammonia and other gut derived toxins that factor prominently in the underlying cause of mild hepatic encephalopathy (MHE), a neurocognitive disorder present in a majority of patients with cirrhosis of the liver. Because MHE leads to a...

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- UCL Liver Failure Group presented data from two studies with OCR-002 (L-ornithine phenylacetate) that suggest the potential for this novel therapeutic agent to impact multiple aspects of liver disease and its complications. OCR-002 is licensed to Ocera Therapeutics, Inc. of San Diego, California. The data, presented at the 60th annual meeting of the American Association for the Study of Liver Diseases, is comprised of a set of studies evaluating the...

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus (itching) in patients with chronic liver disease. The data were presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in a presentation titled, "Oral AST-120 (Spherical Carbon Adsorbent) Improves Pruritus and Lowers Serum Bile Acids in Patients with Cirrhosis of Various Etiologies." These...

2009-10-08 11:38:21

The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found. Acute liver failure occurs when cells in the liver die quickly, resulting in toxins being released into the bloodstream and brain. Patients often end up in a hepatic coma as a result of toxins not being cleared by the failing...

2009-09-09 11:52:21

Up to 80 percent of cirrhotic patients develop difficulties with cognitive function A recent study by Jasmohan Bajaj, M.D., and colleagues from Virginia Commonwealth University and McGuire VA Medical Center found that patients with cirrhosis of the liver who developed minimal hepatic encephalopathy (MHE) had a 16% rate of motor vehicle crashes compared to only 4% of those without MHE over one year. The rate of accidents was also significantly higher than the state annual crash rate of...

2009-06-30 07:00:00

SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, today announced it has closed a $60 million Series C financing. New investors Bay City Capital and Panorama Capital co-led the financing. Series A and B investors Highland Capital Partners, NEA, and Sofinnova Ventures also participated. (Logo:...

2009-06-29 09:49:21

A research article to be published June 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team lead by Dr. Gabriela Beatriz Acosta, observed that the activity of GS was increased in the hippocampus in PH rats. There was a significant decrease in glutamate uptake in both brain areas, which was more marked in the hippocampus. The decrease in glutamate uptake might be caused by deficient transport function and persistent glutamate activity, which is not...

2009-06-02 07:00:00

- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis. The data were presented as part of the 2009 Digestive Disease Week meeting. The abstract is titled "Pharmacokinetic (PK) and Safety Analyses of a Novel Ammonia-Reducing Agent in Healthy Adults and Patients with Cirrhosis." (Logo:...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related